model updat updat model actual compani file made
minor run rate revenu expens adjust weve lower neulasta revenu
reflect on-going eros weve adjust incom expens
estim reflect compani guidanc relat share beigen income/loss
begin project ep vs old risk includ clinic
regulatori commerci headwind tp outperform rate unchang
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc biotechnolog compani engag discoveri
develop manufactur market human therapeut
blue sky scenario assum tvgr better current
assumpt base-busi greater current
forecast assum greater expect growth biosimilar
franchis slower expect declin base busi
also assum posit data readout pipelin asset
base busi sale poorer growth profil biosimilar
busi key pipelin asset assum slower expect
growth biosimilar franchis regulatori headwind drug
approv ip litig also assum neg data readout
 close
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
